Pharmaceutical Technology on MSN12d
ITM targets US approval for radiopharmaceutical after Phase III readout
ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 ...
Cure Today12d
177Lu-edotreotide May Delay Progression in Neuroendocrine Tumor Subset
Patients treated with 177Lu-edotreotide had a significantly longer median progression-free survival compared to those receiving Afinitor The findings were announced in a news release from the drug’s ...
Hosted on MSN1mon
ITM’s radiotherapeutic beats out standard-of-care in Phase III trial
Patients were randomised to receive ITM-11 with a nephroprotective amino acid solution every three months, or Afinitor 10 mg daily for up to 30 months or until the disease progressed. Andrew Cavey ...
pharmaphorum12y
Afinitor reduces tumours in rare disease, says Novartis
Novartis has announced that phase 3 clinical trials data published in the Lancet showed significant benefit of its cancer drug, Afinitor (everolimus) in patients with non-cancerous tumours ...
pharmaphorum8y
Novartis' Afinitor gets new EU cancer use
Afinitor (everolimus) has been approved in the EU for advanced, progressive, non-functional neuroendocrine tumours (NETs) of gastrointestinal and lung origin and is the first oral therapy for this ...